Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53-Deficient Cancers.

Goswami MT, VanDenBerg KR, Han S, Wang LL, Singh B, Weiss T, Barlow M, Kamberov S, Wilder-Romans K, Rhodes DR, Feng FY, Tomlins SA.

Mol Cancer Res. 2019 May 20. doi: 10.1158/1541-7786.MCR-19-0144. [Epub ahead of print]

PMID:
31110156
2.

Informing a Risk Prediction Model for Binary Outcomes with External Coefficient Information.

Cheng W, Taylor JMG, Gu T, Tomlins SA, Mukherjee B.

J R Stat Soc Ser C Appl Stat. 2019 Jan;68(1):121-139. doi: 10.1111/rssc.12306. Epub 2018 Aug 13.

PMID:
31105344
3.

Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management.

Koo KM, Mainwaring PN, Tomlins SA, Trau M.

Nat Rev Urol. 2019 May;16(5):302-317. doi: 10.1038/s41585-019-0178-2. Review.

PMID:
30962568
4.

TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer.

Kaur HB, Lu J, Guedes LB, Maldonado L, Reitz L, Barber JR, De Marzo AM, Tomlins SA, Sfanos KS, Eisenberger M, Schaeffer EM, Joshu CE, Lotan TL.

Hum Pathol. 2019 May;87:95-102. doi: 10.1016/j.humpath.2019.02.006. Epub 2019 Mar 6.

PMID:
30851334
5.

SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post-prostatectomy.

Faisal FA, Kaur HB, Tosoian JJ, Tomlins SA, Schaeffer EM, Lotan TL.

Prostate Cancer Prostatic Dis. 2019 Mar 8. doi: 10.1038/s41391-019-0139-0. [Epub ahead of print]

PMID:
30850708
6.

Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer.

Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, Karnes RJ, Ross AE, Schaeffer EM, Rubin MA, Trock B, Klein EA, Den RB, Tomlins SA, Spratt DE, Davicioni E, Sboner A, Barbieri CE.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00036. Epub 2018 Jul 24.

7.

Genetic Characteristics of Aldosterone-Producing Adenomas in Blacks.

Nanba K, Omata K, Gomez-Sanchez CE, Stratakis CA, Demidowich AP, Suzuki M, Thompson LDR, Cohen DL, Luther JM, Gellert L, Vaidya A, Barletta JA, Else T, Giordano TJ, Tomlins SA, Rainey WE.

Hypertension. 2019 Apr;73(4):885-892. doi: 10.1161/HYPERTENSIONAHA.118.12070.

PMID:
30739536
8.

Tubulocystic renal cell carcinoma: a distinct clinicopathologic entity with a characteristic genomic profile.

Sarungbam J, Mehra R, Tomlins SA, Smith SC, Jayakumaran G, Al-Ahmadie H, Gopalan A, Sirintrapun SJ, Fine SW, Zhang Y, Amin MB, Reuter VE, Chen YB, Tickoo SK.

Mod Pathol. 2019 May;32(5):701-709. doi: 10.1038/s41379-018-0185-5. Epub 2019 Jan 8.

PMID:
30622286
9.

Multiclonality and Marked Branched Evolution of Low-Grade Endometrioid Endometrial Carcinoma.

Lazo de la Vega L, Samaha MC, Hu K, Bick NR, Siddiqui J, Hovelson DH, Liu CJ, Carter CS, Cho KR, Sciallis AP, Tomlins SA.

Mol Cancer Res. 2019 Mar;17(3):731-740. doi: 10.1158/1541-7786.MCR-18-1178. Epub 2019 Jan 4.

PMID:
30610106
10.

Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas.

Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnard TJ, Mahal BA, Gibb EA, Liu Y, Davicioni E, Duska LR, Posadas EM, Jolly S, Spratt DE, Nguyen PL, Maher CA, Small EJ, Feng FY.

Clin Cancer Res. 2019 Apr 15;25(8):2450-2457. doi: 10.1158/1078-0432.CCR-18-3121. Epub 2018 Dec 20.

PMID:
30573691
11.

Somatic mutations in adrenocortical carcinoma with hyperaldosteronism.

Mouat IC, Omata K, McDaniel AS, Hattangady N, Talapatra D, Cani AK, Hovelson DH, Tomlins SA, Rainey W, Hammer G, Giordano TJ, Else T.

Endocr Relat Cancer. 2018 Nov 1. pii: ERC-18-0385.R2. doi: 10.1530/ERC-18-0385. [Epub ahead of print]

PMID:
30475217
12.

Transcriptomic heterogeneity in multifocal prostate cancer.

Salami SS, Hovelson DH, Kaplan JB, Mathieu R, Udager AM, Curci NE, Lee M, Plouffe KR, de la Vega LL, Susani M, Rioux-Leclercq N, Spratt DE, Morgan TM, Davenport MS, Chinnaiyan AM, Cyrta J, Rubin MA, Shariat SF, Tomlins SA, Palapattu GS.

JCI Insight. 2018 Nov 2;3(21). pii: 123468. doi: 10.1172/jci.insight.123468.

13.

Cellular and Genetic Causes of Idiopathic Hyperaldosteronism.

Omata K, Satoh F, Morimoto R, Ito S, Yamazaki Y, Nakamura Y, Anand SK, Guo Z, Stowasser M, Sasano H, Tomlins SA, Rainey WE.

Hypertension. 2018 Oct;72(4):874-880. doi: 10.1161/HYPERTENSIONAHA.118.11086.

PMID:
30354720
14.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Oct 18;175(3):889. doi: 10.1016/j.cell.2018.10.019. No abstract available.

15.

Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.

Mehra R, Salami SS, Lonigro R, Bhalla R, Siddiqui J, Cao X, Spratt DE, Palapattu GS, Palanisamy N, Wei JT, Chinnaiyan AM, Tomlins SA.

Med Oncol. 2018 Oct 5;35(12):152. doi: 10.1007/s12032-018-1212-6.

PMID:
30291535
16.

Managing Nonmetastatic Castration-resistant Prostate Cancer.

Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, Shore N, Smith M, Sweeney C, Tombal B, Tomlins SA, de Bono JS.

Eur Urol. 2019 Feb;75(2):285-293. doi: 10.1016/j.eururo.2018.07.035. Epub 2018 Aug 14. Review.

17.

Targeted Molecular Characterization of Aldosterone-Producing Adenomas in White Americans.

Nanba K, Omata K, Else T, Beck PCC, Nanba AT, Turcu AF, Miller BS, Giordano TJ, Tomlins SA, Rainey WE.

J Clin Endocrinol Metab. 2018 Oct 1;103(10):3869-3876. doi: 10.1210/jc.2018-01004.

PMID:
30085035
18.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Jul 26;174(3):758-769.e9. doi: 10.1016/j.cell.2018.06.039. Epub 2018 Jul 19. Erratum in: Cell. 2018 Oct 18;175(3):889.

19.

Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.

Hovelson DH, Udager AM, McDaniel AS, Grivas P, Palmbos P, Tamura S, Lazo de la Vega L, Palapattu G, Veeneman B, El-Sawy L, Sadis SE, Morgan TM, Montgomery JS, Weizer AZ, Day KC, Neamati N, Liebert M, Keller ET, Day ML, Mehra R, Tomlins SA.

Eur Urol. 2018 Dec;74(6):741-753. doi: 10.1016/j.eururo.2018.06.047. Epub 2018 Jul 20.

PMID:
30033047
20.

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.

Boudadi K, Suzman DL, Anagnostou V, Fu W, Luber B, Wang H, Niknafs N, White JR, Silberstein JL, Sullivan R, Dowling D, Harb R, Nirschl TR, Veeneman BA, Tomlins SA, Wang Y, Jendrisak A, Graf RP, Dittamore R, Carducci MA, Eisenberger MA, Haffner MC, Meeker AK, Eshleman JR, Luo J, Velculescu VE, Drake CG, Antonarakis ES.

Oncotarget. 2018 Jun 19;9(47):28561-28571. doi: 10.18632/oncotarget.25564. eCollection 2018 Jun 19.

21.

Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma.

Udager AM, McDaniel AS, Hovelson DH, Fields K, Salami SS, Kaffenberger SD, Spratt DE, Montgomery JS, Weizer AZ, Reichert ZR, Alva AS, Chinnaiyan AM, Tomlins SA, Mehra R.

Eur Urol. 2018 Oct;74(4):529-531. doi: 10.1016/j.eururo.2018.06.019. Epub 2018 Jul 3. No abstract available.

PMID:
29980330
22.

A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer.

Zhao S, Leonardson A, Geybels MS, McDaniel AS, Yu M, Kolb S, Zong H, Carter K, Siddiqui J, Cheng A, Wright JL, Pritchard CC, Lance R, Troyer D, Fan JB, Ostrander EA, Dai JY, Tomlins SA, Feng Z, Stanford JL.

Prostate. 2018 Jun 28. doi: 10.1002/pros.23667. [Epub ahead of print]

23.

Interstitial assessment of aggressive prostate cancer by physio-chemical photoacoustics: An ex vivo study with intact human prostates.

Huang S, Qin Y, Chen Y, Pan J, Xu C, Wu D, Chao WY, Wei JT, Tomlins SA, Wang X, Fowlkes JB, Carson PL, Cheng Q, Xu G.

Med Phys. 2018 Jun 23. doi: 10.1002/mp.13061. [Epub ahead of print]

PMID:
29935081
24.

Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer.

Kaur HB, Guedes LB, Lu J, Maldonado L, Reitz L, Barber JR, De Marzo AM, Tosoian JJ, Tomlins SA, Schaeffer EM, Joshu CE, Sfanos KS, Lotan TL.

Mod Pathol. 2018 Oct;31(10):1539-1552. doi: 10.1038/s41379-018-0083-x. Epub 2018 May 30.

25.

Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.

Singhal U, Wang Y, Henderson J, Niknafs YS, Qiao Y, Gursky A, Zaslavsky A, Chung JS, Smith DC, Karnes RJ, Chang SL, Feng FY, Palapattu GS, Taichman RS, Chinnaiyan AM, Tomlins SA, Morgan TM.

Mol Cancer Res. 2018 Apr;16(4):643-654. doi: 10.1158/1541-7786.MCR-17-0539. Epub 2018 Feb 16.

26.

Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.

Ankerst DP, Goros M, Tomlins SA, Patil D, Feng Z, Wei JT, Sanda MG, Gelfond J, Thompson IM, Leach RJ, Liss MA.

Eur Urol Focus. 2019 Jan;5(1):54-61. doi: 10.1016/j.euf.2018.01.010. Epub 2018 Feb 13.

27.

Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections.

Spratt DE, Suresh K, Osawa T, Schipper M, Jackson WC, Abugharib A, Lebastchi A, Smith D, Montgomery JS, Palapattu GS, Priya Kunju L, Wu A, Lew M, Tomlins SA, Chinnaiyan AM, Weizer AZ, Hafez KS, Kaffenberger SD, Udager A, Mehra R.

Med Oncol. 2018 Jan 31;35(3):21. doi: 10.1007/s12032-018-1090-y.

PMID:
29387987
28.

Molecular Biomarkers in the Clinical Management of Prostate Cancer.

Udager AM, Tomlins SA.

Cold Spring Harb Perspect Med. 2018 Nov 1;8(11). pii: a030601. doi: 10.1101/cshperspect.a030601. Review.

PMID:
29311125
29.

Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.

Ohe C, Smith SC, Sirohi D, Divatia M, de Peralta-Venturina M, Paner GP, Agaimy A, Amin MB, Argani P, Chen YB, Cheng L, Colecchia M, Compérat E, Werneck da Cunha I, Epstein JI, Gill AJ, Hes O, Hirsch MS, Jochum W, Kunju LP, Maclean F, Magi-Galluzzi C, McKenney JK, Mehra R, Nesi G, Osunkoya AO, Picken MM, Rao P, Reuter VE, de Oliveira Salles PG, Schultz L, Tickoo SK, Tomlins SA, Trpkov K, Amin MB.

Am J Surg Pathol. 2018 Mar;42(3):279-292. doi: 10.1097/PAS.0000000000001000.

PMID:
29309300
30.

Aldosterone-Producing Cell Clusters Frequently Harbor Somatic Mutations and Accumulate With Age in Normal Adrenals.

Omata K, Anand SK, Hovelson DH, Liu CJ, Yamazaki Y, Nakamura Y, Ito S, Satoh F, Sasano H, Rainey WE, Tomlins SA.

J Endocr Soc. 2017 May 12;1(7):787-799. doi: 10.1210/js.2017-00134. eCollection 2017 Jul 1.

31.

Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.

Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D, Lonigro RJ, Cao X, Tomlins SA, Mehra R, Cooney KA, Montgomery B, Antonarakis ES, Shevrin DH, Corn PG, Whang YE, Smith DC, Caram MV, Knudsen KE, Stadler WM, Feng FY, Chinnaiyan AM.

J Clin Oncol. 2018 Apr 1;36(10):991-999. doi: 10.1200/JCO.2017.75.7310. Epub 2017 Dec 20.

32.

The CARMA3-Bcl10-MALT1 Signalosome Drives NFκB Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer.

Ekambaram P, Lee JL, Hubel NE, Hu D, Yerneni S, Campbell PG, Pollock N, Klei LR, Concel VJ, Delekta PC, Chinnaiyan AM, Tomlins SA, Rhodes DR, Priedigkeit N, Lee AV, Oesterreich S, McAllister-Lucas LM, Lucas PC.

Cancer Res. 2018 Mar 1;78(5):1225-1240. doi: 10.1158/0008-5472.CAN-17-1089. Epub 2017 Dec 19.

33.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13.

34.

Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms.

Paoletti C, Cani AK, Larios JM, Hovelson DH, Aung K, Darga EP, Cannell EM, Baratta PJ, Liu CJ, Chu D, Yazdani M, Blevins AR, Sero V, Tokudome N, Thomas DG, Gersch C, Schott AF, Wu YM, Lonigro R, Robinson DR, Chinnaiyan AM, Bischoff FZ, Johnson MD, Park BH, Hayes DF, Rae JM, Tomlins SA.

Cancer Res. 2018 Feb 15;78(4):1110-1122. doi: 10.1158/0008-5472.CAN-17-2686. Epub 2017 Dec 12.

35.

Aldosterone-Producing Cell Clusters in Normal and Pathological States.

Omata K, Tomlins SA, Rainey WE.

Horm Metab Res. 2017 Dec;49(12):951-956. doi: 10.1055/s-0043-122394. Epub 2017 Dec 4. Review.

36.

Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy.

Hovelson DH, Liu CJ, Wang Y, Kang Q, Henderson J, Gursky A, Brockman S, Ramnath N, Krauss JC, Talpaz M, Kandarpa M, Chugh R, Tuck M, Herman K, Grasso CS, Quist MJ, Feng FY, Haakenson C, Langmore J, Kamberov E, Tesmer T, Husain H, Lonigro RJ, Robinson D, Smith DC, Alva AS, Hussain MH, Chinnaiyan AM, Tewari M, Mills RE, Morgan TM, Tomlins SA.

Oncotarget. 2017 Sep 22;8(52):89848-89866. doi: 10.18632/oncotarget.21163. eCollection 2017 Oct 27.

37.

Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.

Skala SL, Xiao H, Udager AM, Dhanasekaran SM, Shukla S, Zhang Y, Landau C, Shao L, Roulston D, Wang L, Siddiqui J, Cao X, Magi-Galluzzi C, Zhang M, Osunkoya AO, Smith SC, McKenney JK, Betz BL, Myers JL, Chinnaiyan AM, Tomlins SA, Mehra R.

Mod Pathol. 2018 Jan;31(1):179-197. doi: 10.1038/modpathol.2017.99. Epub 2017 Aug 25.

38.

Integrative clinical genomics of metastatic cancer.

Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, Cao X, Rabban E, Kumar-Sinha C, Raymond V, Schuetze S, Alva A, Siddiqui J, Chugh R, Worden F, Zalupski MM, Innis J, Mody RJ, Tomlins SA, Lucas D, Baker LH, Ramnath N, Schott AF, Hayes DF, Vijai J, Offit K, Stoffel EM, Roberts JS, Smith DC, Kunju LP, Talpaz M, Cieślik M, Chinnaiyan AM.

Nature. 2017 Aug 17;548(7667):297-303. doi: 10.1038/nature23306. Epub 2017 Aug 2.

39.

Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable FGFR3 Amplifications.

Lazo de la Vega L, McHugh JB, Cani AK, Kunder K, Walocko FM, Liu CJ, Hovelson DH, Robinson D, Chinnaiyan AM, Tomlins SA, Harms PW.

Mol Cancer Res. 2017 Nov;15(11):1551-1557. doi: 10.1158/1541-7786.MCR-17-0135. Epub 2017 Aug 3.

40.

Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.

Sanda MG, Feng Z, Howard DH, Tomlins SA, Sokoll LJ, Chan DW, Regan MM, Groskopf J, Chipman J, Patil DH, Salami SS, Scherr DS, Kagan J, Srivastava S, Thompson IM Jr, Siddiqui J, Fan J, Joon AY, Bantis LE, Rubin MA, Chinnayian AM, Wei JT; and the EDRN-PCA3 Study Group, Bidair M, Kibel A, Lin DW, Lotan Y, Partin A, Taneja S.

JAMA Oncol. 2017 Aug 1;3(8):1085-1093. doi: 10.1001/jamaoncol.2017.0177.

41.

Fibulin-3 promotes muscle-invasive bladder cancer.

Han AL, Veeneman BA, El-Sawy L, Day KC, Day ML, Tomlins SA, Keller ET.

Oncogene. 2017 Sep 14;36(37):5243-5251. doi: 10.1038/onc.2017.149. Epub 2017 May 15.

PMID:
28504717
42.

Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.

Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, Spratt DE, Feng FY.

JAMA Oncol. 2017 Dec 1;3(12):1663-1672. doi: 10.1001/jamaoncol.2017.0751.

43.

Minimally Invasive Inguinal Lymphadenectomy in the Management of Penile Carcinoma.

Russell CM, Salami SS, Niemann A, Weizer AZ, Tomlins SA, Morgan TM, Montgomery JS.

Urology. 2017 Aug;106:113-118. doi: 10.1016/j.urology.2017.04.022. Epub 2017 Apr 24.

PMID:
28450202
44.

Molecular Profiling of Multiple Primary Merkel Cell Carcinoma to Distinguish Genetically Distinct Tumors From Clonally Related Metastases.

Harms KL, Lazo de la Vega L, Hovelson DH, Rahrig S, Cani AK, Liu CJ, Fullen DR, Wang M, Andea AA, Bichakjian CK, Johnson TM, Tomlins SA, Harms PW.

JAMA Dermatol. 2017 Jun 1;153(6):505-512. doi: 10.1001/jamadermatol.2017.0507.

45.

Histopathological Classification of Cross-Sectional Image-Negative Hyperaldosteronism.

Yamazaki Y, Nakamura Y, Omata K, Ise K, Tezuka Y, Ono Y, Morimoto R, Nozawa Y, Gomez-Sanchez CE, Tomlins SA, Rainey WE, Ito S, Satoh F, Sasano H.

J Clin Endocrinol Metab. 2017 Apr 1;102(4):1182-1192. doi: 10.1210/jc.2016-2986.

46.

Genetic and Histopathologic Intertumor Heterogeneity in Primary Aldosteronism.

Omata K, Yamazaki Y, Nakamura Y, Anand SK, Barletta JA, Sasano H, Rainey WE, Tomlins SA, Vaidya A.

J Clin Endocrinol Metab. 2017 Jun 1;102(6):1792-1796. doi: 10.1210/jc.2016-4007.

47.

Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer.

Barnett CL, Tomlins SA, Underwood DJ, Wei JT, Morgan TM, Montie JE, Denton BT.

Med Decis Making. 2017 Oct;37(7):815-826. doi: 10.1177/0272989X17696996. Epub 2017 Mar 31.

PMID:
28363265
48.

Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay.

Torres A, Alshalalfa M, Tomlins SA, Erho N, Gibb EA, Chelliserry J, Lim L, Lam LLC, Faraj SF, Bezerra SM, Davicioni E, Yousefi K, Ross AE, Netto GJ, Schaeffer EM, Lotan TL.

J Mol Diagn. 2017 May;19(3):475-484. doi: 10.1016/j.jmoldx.2017.01.007. Epub 2017 Mar 21.

49.

A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma.

Smith SC, Sirohi D, Ohe C, McHugh JB, Hornick JL, Kalariya J, Karia S, Snape K, Hodgson SV, Cani AK, Hovelson D, Luthringer DJ, Martignoni G, Chen YB, Tomlins SA, Mehra R, Amin MB.

Histopathology. 2017 Jul;71(1):42-52. doi: 10.1111/his.13183. Epub 2017 Apr 12.

50.

Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study.

Jackson WC, Desai NB, Abugharib AE, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Folkert M, Laine A, Hannan R, Zumsteg ZS, Sandler H, Hamstra DA, Montgomery JS, Miller DC, Kozminski MA, Hollenbeck BK, Hearn JW, Palapattu G, Tomlins SA, Mehra R, Morgan TM, Feng FY, Spratt DE.

BJU Int. 2017 Sep;120(3):351-357. doi: 10.1111/bju.13792. Epub 2017 Feb 26.

Supplemental Content

Loading ...
Support Center